These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16863913)

  • 1. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C.
    Broxmeyer HE; Pelus LM; Kim CH; Hangoc G; Cooper S; Hromas R
    Exp Hematol; 2006 Aug; 34(8):1069-77. PubMed ID: 16863913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE; Cooper S; Hangoc G; Chang CH
    Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal cell-derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro.
    Broxmeyer HE; Cooper S; Hangoc G; Kim CH
    Stem Cells Dev; 2005 Apr; 14(2):199-203. PubMed ID: 15910246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity.
    Hromas R; Cooper S; Broxmeyer HE
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):163-6. PubMed ID: 12172984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha.
    Cooper S; Mantel C; Broxmeyer HE
    Exp Hematol; 1994 Feb; 22(2):186-93. PubMed ID: 8299739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
    Broxmeyer HE; Orazi A; Hague NL; Sledge GW; Rasmussen H; Gordon MS
    Blood Cells Mol Dis; 1998 Mar; 24(1):14-30. PubMed ID: 9516378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
    Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
    Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein-1 alpha.
    Maze R; Sherry B; Kwon BS; Cerami A; Broxmeyer HE
    J Immunol; 1992 Aug; 149(3):1004-9. PubMed ID: 1634758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.
    Broxmeyer HE; Cooper S; Hague N; Benninger L; Sarris A; Cornetta K; Vadhan-Raj S; Hendrie P; Mantel C
    Ann Hematol; 1995 Nov; 71(5):235-46. PubMed ID: 7492626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.
    Djazayeri K; Szilvássy Z; Peitl B; Németh J; Nagy L; Kiss A; Szabó B; Benko I
    Eur J Pharmacol; 2005 Oct; 522(1-3):122-9. PubMed ID: 16213483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects of 1-beta-D-arabinofuranosylcytosine and 6-thioguanine in vitro on granulocytic progenitor cells.
    Greenberg PL; VanKersen I; Mosny S
    Cancer Res; 1976 Dec; 36(12):4412-7. PubMed ID: 1069606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
    Naldini A; Fleischmann WR
    J Biol Response Mod; 1987 Oct; 6(5):546-55. PubMed ID: 3119781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
    Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
    Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics.
    Kim WY; Broxmeyer HE; Han IS; Park DH; Lee KM; Vinay DS; Kwon BS
    J Hematother Stem Cell Res; 2003 Feb; 12(1):107-13. PubMed ID: 12662441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
    Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin dependent kinase inhibitors differentially modulate synergistic cytokine responsiveness of hematopoietic progenitor cells.
    Broxmeyer HE; Franklin DS; Cooper S; Hangoc G; Mantel C
    Stem Cells Dev; 2012 Jul; 21(10):1597-603. PubMed ID: 21936707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy.
    Gardner RV; Astle CM; Harrison DE
    Exp Hematol; 1997 Jun; 25(6):495-501. PubMed ID: 9197327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction: role of beta-catenin transduction and cell dose.
    Templin C; Kotlarz D; Faulhaber J; Schnabel S; Grote K; Salguero G; Luchtefeld M; Hiller KH; Jakob P; Naim HY; Schieffer B; Hilfiker-Kleiner D; Landmesser U; Limbourg FP; Drexler H
    J Mol Cell Cardiol; 2008 Sep; 45(3):394-403. PubMed ID: 18671980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13.
    Stich S; Loch A; Leinhase I; Neumann K; Kaps C; Sittinger M; Ringe J
    Eur J Cell Biol; 2008 Jun; 87(6):365-76. PubMed ID: 18501472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.